Table 6.

Anticancer drugs inducing heart failure/left ventricular cardiac dysfunction

Heart failure/LV dysfunction induced by anticancer drugs
Type I	Anthracyclines (doxorubicin, daunorubicin, epirubicin)
	Alkylating agent (cyclophosphamide)
	Taxanes (docetaxel, paclitaxel)
Type II	HER2 targeting antibodies (trastuzumab, pertuzumab, adotrastuzumab)
	HER2 targeting tyrosine kinase inhibitors (lapatinib)
	(Tyrosine) kinase inhibitors (sunitinib, sorafenib, dobrafenib, ponatinib)
	Proteasome inhibitors (bortezomib, karfilzomib)